Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease

BACKGROUND: Although the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non‐alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the predictio...

Descripción completa

Detalles Bibliográficos
Autores principales: Munteanu, Mona, Pais, Raluca, Peta, Valentina, Deckmyn, Olivier, Moussalli, Joseph, Ngo, Yen, Rudler, Marika, Lebray, Pascal, Charlotte, Frederic, Thibault, Vincent, Lucidarme, Olivier, Ngo, An, Imbert‐Bismut, Françoise, Housset, Chantal, Thabut, Dominique, Ratziu, Vlad, Poynard, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Prognostic Valuse of Fibrotest in Chronic Liver Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221139/
https://www.ncbi.nlm.nih.gov/pubmed/30334263
http://dx.doi.org/10.1111/apt.14990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221139/
https://www.ncbi.nlm.nih.gov/pubmed/30334263
http://dx.doi.org/10.1111/apt.14990

Ejemplares similares